DE602004028725D1 - Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen - Google Patents
Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungenInfo
- Publication number
- DE602004028725D1 DE602004028725D1 DE602004028725T DE602004028725T DE602004028725D1 DE 602004028725 D1 DE602004028725 D1 DE 602004028725D1 DE 602004028725 T DE602004028725 T DE 602004028725T DE 602004028725 T DE602004028725 T DE 602004028725T DE 602004028725 D1 DE602004028725 D1 DE 602004028725D1
- Authority
- DE
- Germany
- Prior art keywords
- moiety
- peptide
- erythropoietinagonists
- ethylenglycol
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47024603P | 2003-05-12 | 2003-05-12 | |
PCT/US2004/014888 WO2004101600A2 (en) | 2003-05-12 | 2004-05-12 | Novel poly(ethylene glycol) modified compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004028725D1 true DE602004028725D1 (de) | 2010-09-30 |
Family
ID=33452386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004028725T Active DE602004028725D1 (de) | 2003-05-12 | 2004-05-12 | Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen |
Country Status (16)
Country | Link |
---|---|
US (1) | US20050107297A1 (de) |
EP (2) | EP2336162A1 (de) |
JP (2) | JP2007530440A (de) |
KR (1) | KR20060028675A (de) |
CN (1) | CN1820024B (de) |
AT (1) | ATE478093T1 (de) |
AU (1) | AU2004238869B2 (de) |
BR (1) | BRPI0411160A (de) |
CA (1) | CA2525464A1 (de) |
DE (1) | DE602004028725D1 (de) |
EA (1) | EA010016B1 (de) |
IS (1) | IS8169A (de) |
MX (1) | MXPA05012315A (de) |
NO (1) | NO20055849L (de) |
NZ (1) | NZ544024A (de) |
WO (1) | WO2004101600A2 (de) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2204193A3 (de) * | 2003-05-12 | 2010-08-18 | Affymax, Inc. | Spacer-Bestandteile für Poly(ethylenglykol)-modifizierte Verbindungen auf Peptidbasis |
DE602004020610D1 (de) | 2003-05-12 | 2009-05-28 | Affymax Inc | Neue, an den erythropoietinrezeptor bindende peptide |
US7710923B2 (en) * | 2004-05-07 | 2010-05-04 | Interdigital Technology Corporation | System and method for implementing a media independent handover |
US7589063B2 (en) | 2004-12-14 | 2009-09-15 | Aplagen Gmbh | Molecules which promote hematopoiesis |
KR20180110192A (ko) | 2004-11-12 | 2018-10-08 | 바이엘 헬스케어 엘엘씨 | Fviii의 부위 지향 변형 |
US7824919B2 (en) * | 2005-03-04 | 2010-11-02 | Dr. Reddy's Laboratories Limited | Method for analyzing activated polyethylene glycol compounds |
CA2648732A1 (en) * | 2005-06-23 | 2006-12-28 | Aplagen Gmbh | Supravalent compounds |
CN101002945B (zh) * | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
ATE513853T1 (de) | 2006-02-23 | 2011-07-15 | Fibrex Medical Res & Dev Gmbh | Peptide und peptidderivate sowie pharmazeutische zusammensetzungen, die diese enthalten |
BRPI0709014A2 (pt) * | 2006-03-09 | 2011-06-21 | Aplagen Gmbh | moléculas modifcadas que promovem hematopoise |
EP2275142A3 (de) | 2006-06-30 | 2011-05-11 | Andre Koltermann | Konjugate für Krebs-Immuntherapie |
WO2008095004A2 (en) * | 2007-01-31 | 2008-08-07 | Affymax, Inc. | Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules |
TW201307390A (zh) * | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶(hepcidin)、海帕西啶拮抗劑及使用方法 |
US8420598B2 (en) * | 2007-04-20 | 2013-04-16 | B & L Delipharm Corp. | Mono modified exendin with polyethylene glycol or its derivatives and uses thereof |
WO2009002947A2 (en) * | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
EP2018835B1 (de) | 2007-07-09 | 2014-03-05 | Augustinus Bader | Wirkstoff abgebendes Pflaster |
AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
ES2962777T3 (es) | 2007-11-15 | 2024-03-21 | Amgen Inc | Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral |
CN101456911A (zh) * | 2007-12-12 | 2009-06-17 | 江苏豪森药业股份有限公司 | 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途 |
JP5701064B2 (ja) | 2008-01-25 | 2015-04-15 | アムジエン・インコーポレーテツド | フェロポーチン抗体およびその使用方法 |
US9315577B2 (en) | 2008-05-01 | 2016-04-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
US8088890B2 (en) | 2008-09-26 | 2012-01-03 | Fibrex Medical Research & Development Gmbh | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
CA2742871C (en) | 2008-11-13 | 2018-10-23 | Herb Lin | Methods and compositions for regulating iron homeostasis by modulation of bmp-6 |
MX2011010050A (es) | 2009-03-25 | 2011-12-14 | Univ Texas | Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos. |
WO2011050333A1 (en) | 2009-10-23 | 2011-04-28 | Amgen Inc. | Vial adapter and system |
US9061097B2 (en) | 2010-06-07 | 2015-06-23 | Amgen Inc. | Drug delivery device |
EP2590666B1 (de) | 2010-07-06 | 2017-04-26 | Augustinus Bader | Topische anwendung von erythropoetin zur behandlung von verletzungen der hornhaut |
MX341790B (es) | 2011-03-31 | 2016-09-02 | Amgen Inc | Adaptador de viales y sistema. |
CA2833748C (en) | 2011-04-20 | 2019-07-16 | Amgen Inc. | Autoinjector apparatus |
ES2729993T3 (es) | 2011-10-14 | 2019-11-07 | Amgen Inc | Inyector y procedimiento de ensamblaje |
EP2922590B1 (de) | 2012-11-21 | 2020-02-05 | Amgen Inc. | Arzneimittelabgabevorrichtung |
EP3593839A1 (de) | 2013-03-15 | 2020-01-15 | Amgen Inc. | Arzneimittelkassette |
CN105263514B (zh) | 2013-03-15 | 2019-04-26 | 本质生命科学有限公司 | 抗铁调素抗体及其用途 |
TWI580451B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法 |
LT2976117T (lt) | 2013-03-22 | 2021-02-25 | Amgen Inc. | Purkštuvas ir surinkimo būdas |
AU2014340171B2 (en) | 2013-10-24 | 2019-05-30 | Amgen Inc. | Injector and method of assembly |
WO2015061389A1 (en) | 2013-10-24 | 2015-04-30 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
CA3193070A1 (en) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Autoinjector with shock reducing elements |
JP6817074B2 (ja) | 2014-06-03 | 2021-01-20 | アムジエン・インコーポレーテツド | 制御可能な薬物送達システム及び使用方法 |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
NZ730186A (en) | 2014-09-22 | 2020-04-24 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
MX2021014323A (es) | 2014-10-14 | 2023-02-02 | Amgen Inc | Dispositivo de inyección de fármaco con indicadores visuales y audibles. |
EP3233163B1 (de) | 2014-12-19 | 2021-10-13 | Amgen Inc. | Medikamentenabgabevorrichtung mit näherungssensor |
US11357916B2 (en) | 2014-12-19 | 2022-06-14 | Amgen Inc. | Drug delivery device with live button or user interface field |
CA3069716C (en) | 2015-02-17 | 2021-11-09 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
EP3981450A1 (de) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Arzneimittelabgabevorrichtung mit nadelschutzmechanismus mit abstimmbarem widerstandsschwellwert gegenüber der bewegung des nadelschutzes |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
JP7082568B2 (ja) | 2015-12-09 | 2022-06-08 | アムジエン・インコーポレーテツド | 信号伝達キャップ付き自動注射器 |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
EP3721922B1 (de) | 2016-03-15 | 2022-05-04 | Amgen Inc. | Verringerung der wahrscheinlichkeit auf glasbruch in arzneimittelabgabevorrichtungen |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
CA3018426A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
GB201609083D0 (en) | 2016-05-24 | 2016-07-06 | Syntab Therapeutics Gmbh | Synthetic compound |
EP3465124A1 (de) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Wirkungstestvorrichtungen und verfahren für wirkstofffreisetzungsvorrichtungen |
EP3478342A1 (de) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Arzneimittelabgabevorrichtung mit minimiertem teilebruchrisiko nach aufprallereignissen |
GB201613166D0 (en) | 2016-07-29 | 2016-09-14 | Vectura Ltd | Polymer |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
AU2018210301A1 (en) | 2017-01-17 | 2019-08-01 | Amgen Inc. | Injection devices and related methods of use and assembly |
MX2019009625A (es) | 2017-02-17 | 2019-10-09 | Amgen Inc | Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje. |
EP3582829A1 (de) | 2017-02-17 | 2019-12-25 | Amgen Inc. | Einführmechanismus für eine arzneimittelabgabevorrichtung |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
CA3052482A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
IL303449B1 (en) | 2017-03-09 | 2024-04-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
JP2020511499A (ja) | 2017-03-20 | 2020-04-16 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法 |
CN114588404A (zh) | 2017-03-28 | 2022-06-07 | 美国安进公司 | 柱塞杆和注射器组件系统以及方法 |
AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
MX2019015479A (es) | 2017-06-23 | 2020-02-20 | Amgen Inc | Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador. |
WO2019014014A1 (en) | 2017-07-14 | 2019-01-17 | Amgen Inc. | NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM |
JP2020527376A (ja) | 2017-07-21 | 2020-09-10 | アムジエン・インコーポレーテツド | 薬物容器のためのガス透過性シーリング部材及び組立方法 |
JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
EP3658203B1 (de) | 2017-07-25 | 2022-08-31 | Amgen Inc. | Arzneimittelabgabevorrichtung mit getriebemodul und verwandtes verfahren zur montage |
MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
US11759565B2 (en) | 2017-10-04 | 2023-09-19 | Amgen Inc. | Flow adapter for drug delivery device |
EP4257164A3 (de) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Arzneimittelabgabevorrichtung mit verriegelungsvorrichtung und zugehöriges montageverfahren |
US11464903B2 (en) | 2017-10-09 | 2022-10-11 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
WO2019090086A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
MA50553A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Dispositif d'administration de médicament avec détection de positionnement et de débit |
JP7247174B2 (ja) | 2017-11-10 | 2023-03-28 | アムジエン・インコーポレーテツド | 薬物送達デバイスのプランジャ |
MA50903A (fr) | 2017-11-16 | 2021-05-12 | Amgen Inc | Auto-injecteur avec détection de décrochage et de point d'extrémité |
AU2018368340B2 (en) | 2017-11-16 | 2024-03-07 | Amgen Inc. | Door latch mechanism for drug delivery device |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
US20210228815A1 (en) | 2018-07-24 | 2021-07-29 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
MA53375A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
CA3103681A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
US20210346601A1 (en) | 2018-09-24 | 2021-11-11 | Amgen Inc. | Interventional dosing systems and methods |
WO2020068476A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
AR116679A1 (es) | 2018-10-02 | 2021-06-02 | Amgen Inc | Sistemas de inyección para la administración de fármacos con transmisión de fuerza interna |
US20210338936A1 (en) | 2018-10-05 | 2021-11-04 | Amgen Inc. | Drug delivery device having dose indicator |
EP3866890A1 (de) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Medikamentenabgabevorrichtung mit dämpfungsmechanismus |
CA3109988A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
WO2020091956A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
WO2020091981A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
EP3873567A1 (de) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Arzneimittelabgabevorrichtungen mit teilweisem nadelrückzug |
MX2021012557A (es) | 2019-04-24 | 2021-11-12 | Amgen Inc | Conjuntos y metodos de verificacion de esterilizacion de jeringuillas. |
US20220273887A1 (en) | 2019-08-23 | 2022-09-01 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
WO2021188966A1 (en) * | 2020-03-19 | 2021-09-23 | Massachusetts Institute Of Technology | Sars-cov-2 spike protein binding peptides |
CA3217207A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US469993A (en) | 1892-03-01 | Bolt and nut fastening device | ||
US479245A (en) | 1892-07-19 | Cartridge-reloader | ||
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4677195A (en) * | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
EP0318512B1 (de) | 1986-08-18 | 1998-06-17 | Emisphere Technologies, Inc. | Verabreichungssysteme für arzneimittel |
IE64284B1 (en) * | 1987-08-03 | 1995-07-26 | Ddi Pharmaceuticals | Conjugates of superoxide dismutase |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5006333A (en) * | 1987-08-03 | 1991-04-09 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5114921A (en) * | 1988-05-27 | 1992-05-19 | The Children's Hospital Of Philadelphia | Amphiphilic peptides and use thereof |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
WO1990008822A1 (en) * | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
ES2085297T3 (es) * | 1989-05-27 | 1996-06-01 | Sumitomo Pharma | Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada. |
US5286637A (en) * | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5292654A (en) * | 1990-12-13 | 1994-03-08 | Whitehead Institute For Biomedical Research | Mutant EPO receptor and uses therefor |
CA2288429C (en) * | 1991-03-15 | 2006-04-25 | Synergen, Inc. | Pegylation of polypeptides |
WO1992016192A1 (en) | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
US6153407A (en) * | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
BR9408073A (pt) | 1993-11-16 | 1997-08-12 | Ici Australia Operations | Tratamento anticorrosão de aço revestido com metal tendo revestimentos de alumínio de zinco ou de ligas dos mesmos |
US5830851A (en) * | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
US5580853A (en) * | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
US5919758A (en) * | 1994-03-22 | 1999-07-06 | Beth Israel Deaconess Medical Center | Modified polypeptides with altered biological activity |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
JP2763020B2 (ja) | 1995-04-27 | 1998-06-11 | 日本電気株式会社 | 半導体パッケージ及び半導体装置 |
NZ310778A (en) | 1995-06-07 | 1999-10-28 | Glaxo Group Ltd | Peptides and compounds that bind to a thrombopoietin receptor |
HUP9901069A2 (hu) | 1995-06-07 | 1999-07-28 | Affymax Technologies, N.V. | Az eritropoietin receptorhoz kötődő vegyületek és peptidek |
US6251864B1 (en) | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5677280A (en) * | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US5668110A (en) * | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5683983A (en) * | 1995-06-07 | 1997-11-04 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6346390B1 (en) | 1996-03-08 | 2002-02-12 | Receptron, Inc. | Receptor derived peptides involved in modulation of response to ligand binding |
US6103879A (en) * | 1996-06-21 | 2000-08-15 | Axys Pharmaceuticals, Inc. | Bivalent molecules that form an activating complex with an erythropoietin receptor |
PT964702E (pt) | 1996-08-02 | 2006-12-29 | Ortho Mcneil Pharm Inc | Polipéptidos tendo um único polímero solúvel em água ligado ao n-terminal por covalência |
US5932546A (en) * | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
US6221608B1 (en) * | 1997-01-22 | 2001-04-24 | Ortho Pharmaceutical Corporation | Methods for identifying erythropoietin receptor binding protein |
ES2404074T3 (es) * | 1998-08-06 | 2013-05-23 | Mountain View Pharmaceuticals, Inc. | Conjugados de peg-oxidasa de urato y su uso |
US6783965B1 (en) * | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
CA2351739A1 (en) * | 1998-08-28 | 2000-03-09 | Gryphon Sciences | Polyamide chains of precise length, methods to manufacture them and their conjugates with proteins |
KR100719202B1 (ko) * | 1998-10-23 | 2007-05-16 | 키린-암젠 인코포레이티드 | MPl 수용체에 결합하는 화합물 및 이를 함유하는 제약학적 조성물 |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
ATE315390T1 (de) | 1998-11-17 | 2006-02-15 | Smithkline Beecham Corp | Zyklische polyamine zur behandlung der thrombozytopenie |
JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
AUPQ873300A0 (en) | 2000-07-12 | 2000-08-03 | Medvet Science Pty. Ltd. | A binding motif of a receptor (2) |
DE60032783T2 (de) | 1999-09-24 | 2007-12-06 | Smithkline Beecham Corp. | Thrombopoietinmimetika |
ES2254224T3 (es) * | 1999-09-27 | 2006-06-16 | Chugai Seiyaku Kabushiki Kaisha | Nueva proteina del receptor de hematopoyetina, nr12. |
US6703480B1 (en) | 1999-11-24 | 2004-03-09 | Palani Balu | Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use |
US6858630B2 (en) * | 1999-12-06 | 2005-02-22 | Smithkline Beecham Corporation | Naphthimidazole derivatives and their use as thrombopoietin mimetics |
JP2004512258A (ja) * | 2000-03-21 | 2004-04-22 | ウィスコンシン アルムニ リサーチ ファンデイション | 生物系における細胞応答の調節のための方法および試薬 |
US6777387B2 (en) * | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
EP1149906A1 (de) * | 2000-04-25 | 2001-10-31 | Pliva, Farmaceutska, Industrija, Dionicko Drustvo | Thrombopoietin Rezeptormodulations Peptide |
DE60109625T3 (de) * | 2000-05-15 | 2017-08-03 | F. Hoffmann-La Roche Ag | Flüssige arzneizubereitung enthaltend ein erythropoietin derivat |
BR0111182A (pt) * | 2000-05-26 | 2004-02-25 | Ortho Mcneil Pharm Inc | Peptìdeos neuroprotetores |
PL365664A1 (en) * | 2000-08-02 | 2005-01-10 | Ortho-Mcneil Pharmaceutical, Inc. | Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
SK2772003A3 (en) * | 2000-09-08 | 2003-10-07 | Gryphon Therapeutics Inc | Synthetic erythropoiesis stimulating proteins |
CA2431964C (en) * | 2000-12-20 | 2013-09-10 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
US7767643B2 (en) * | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
US20020183259A1 (en) * | 2001-02-20 | 2002-12-05 | Choe Yun Hwang | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
FR2823220B1 (fr) * | 2001-04-04 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo) |
US20020169128A1 (en) * | 2001-04-09 | 2002-11-14 | Geroge Sigounas | Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
DE60229958D1 (de) * | 2001-06-28 | 2009-01-02 | Mountain View Pharmaceuticals | Polymerstabilisierte proteinasen |
US20030078372A1 (en) * | 2001-09-19 | 2003-04-24 | Scinopharm Singapore | Process for synthesizing peptides by using a PEG polymer support |
UA78726C2 (en) * | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US9125880B2 (en) * | 2002-12-26 | 2015-09-08 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
GEP20084487B (en) * | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof |
DE602004020610D1 (de) * | 2003-05-12 | 2009-05-28 | Affymax Inc | Neue, an den erythropoietinrezeptor bindende peptide |
EP2204193A3 (de) * | 2003-05-12 | 2010-08-18 | Affymax, Inc. | Spacer-Bestandteile für Poly(ethylenglykol)-modifizierte Verbindungen auf Peptidbasis |
CN1823088B (zh) * | 2003-05-12 | 2011-04-13 | 阿费麦克斯公司 | 结合红细胞生成素受体的新肽 |
-
2004
- 2004-05-12 MX MXPA05012315A patent/MXPA05012315A/es active IP Right Grant
- 2004-05-12 DE DE602004028725T patent/DE602004028725D1/de active Active
- 2004-05-12 NZ NZ544024A patent/NZ544024A/en not_active IP Right Cessation
- 2004-05-12 AU AU2004238869A patent/AU2004238869B2/en not_active Ceased
- 2004-05-12 EP EP10173110A patent/EP2336162A1/de not_active Withdrawn
- 2004-05-12 AT AT04760997T patent/ATE478093T1/de not_active IP Right Cessation
- 2004-05-12 WO PCT/US2004/014888 patent/WO2004101600A2/en active Application Filing
- 2004-05-12 EP EP04760997A patent/EP1626983B8/de active Active
- 2004-05-12 KR KR1020057021600A patent/KR20060028675A/ko not_active Application Discontinuation
- 2004-05-12 BR BRPI0411160-5A patent/BRPI0411160A/pt not_active IP Right Cessation
- 2004-05-12 EA EA200501799A patent/EA010016B1/ru not_active IP Right Cessation
- 2004-05-12 CN CN2004800187578A patent/CN1820024B/zh not_active Expired - Fee Related
- 2004-05-12 US US10/844,933 patent/US20050107297A1/en not_active Abandoned
- 2004-05-12 CA CA002525464A patent/CA2525464A1/en not_active Abandoned
- 2004-05-12 JP JP2006532999A patent/JP2007530440A/ja active Pending
-
2005
- 2005-12-02 IS IS8169A patent/IS8169A/is unknown
- 2005-12-09 NO NO20055849A patent/NO20055849L/no not_active Application Discontinuation
-
2012
- 2012-04-13 JP JP2012092128A patent/JP2012158598A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1820024B (zh) | 2011-06-22 |
CN1820024A (zh) | 2006-08-16 |
AU2004238869B2 (en) | 2009-06-25 |
EA010016B1 (ru) | 2008-06-30 |
EP1626983A2 (de) | 2006-02-22 |
EP1626983B1 (de) | 2010-08-18 |
JP2007530440A (ja) | 2007-11-01 |
WO2004101600A2 (en) | 2004-11-25 |
ATE478093T1 (de) | 2010-09-15 |
MXPA05012315A (es) | 2006-04-18 |
WO2004101600A3 (en) | 2006-02-16 |
IS8169A (is) | 2005-12-02 |
KR20060028675A (ko) | 2006-03-31 |
US20050107297A1 (en) | 2005-05-19 |
EP1626983B8 (de) | 2010-12-22 |
JP2012158598A (ja) | 2012-08-23 |
NO20055849L (no) | 2006-02-13 |
NZ544024A (en) | 2009-06-26 |
EA200501799A1 (ru) | 2006-08-25 |
BRPI0411160A (pt) | 2006-07-11 |
EP2336162A1 (de) | 2011-06-22 |
AU2004238869A1 (en) | 2004-11-25 |
CA2525464A1 (en) | 2004-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004028725D1 (de) | Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen | |
CY1113537T1 (el) | Οξινα σκευασματα ινσουλινης με βελτιωμενη σταθεροτητα | |
WO2007127440A3 (en) | Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof | |
TR200400295T2 (tr) | Kimyasal olarak modifiye edilmiş ensülin'in akçiğer yoluyla verilmesi | |
HRP20050683A2 (en) | Polyethylene glycol linked glp-1 compounds | |
DE60214718D1 (de) | Verbindungen mit taxol-verstärkender wirkung | |
ATE357455T1 (de) | Neue effektoren der dipeptidyl peptidase iv zur topischen anwendung | |
CY1117029T1 (el) | Συνεργιστικοι μυκητοκτονοι συνδυασμοι δραστικων ουσιων | |
BR0213655A (pt) | Composição e método para o tratamento dos cabelos e uso do polìmero | |
ATE496626T1 (de) | Komprimierte pharmazeutische zusammensetzungen mit peg und elektrolyten | |
DE602005023315D1 (de) | Antimikrobielle peptide mit einem arginin- und /oder lysin-haltigen motiv | |
ATE333493T1 (de) | Ternäre mischung von bioabbaubaren polyestern und daraus hergestellten produkten | |
BRPI0406800B8 (pt) | "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso | |
AR056137A1 (es) | Un conjugado peptido inmunoglobulina y su uso como antiviral | |
CY1105847T1 (el) | Γραμμικες βασικες ενωσεις που εμφανιζουν δραστικοτητα ανταγωνιστη της nk-2 και σκευασματα αυτων | |
WO2007125210A8 (fr) | Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer ou de l'inflammation | |
WO2004076474A3 (en) | Polyethylene glycol modified interferon compositions and methods of use thereof | |
CY1106967T1 (el) | Παραγωγα πεπτιδιων χαμηλου μοριακου βαρους ως αναστολεις της αλληλεπιδρασης λαμινινης/εντακτινης | |
WO2000058456A3 (en) | Compositions and methods for modifying toxic effects of proteinacious compounds | |
ATE211765T1 (de) | Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen | |
DK1478659T3 (da) | Biologisk aktive peptider | |
ATE338126T1 (de) | Dna-sequenz und rekombinante herstellung eines graminaen-allergens | |
DE69707690T2 (de) | Neue peptide und nootroper wirkstoff | |
CY1114273T1 (el) | Σταθεροποιημενα υγρα σκευασματα ιντερφερονης χωρις ανθρωπινη οροαλβουμινη | |
WO2000029433A3 (en) | 12-25-kda bacterial proteins and their 116-58 kda polymers for use e.g. in anti-tumor vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8381 | Inventor (new situation) |
Inventor name: TUMELTY, DAVID, SUNNYVALE, CALIF., US Inventor name: YIN, QUN, PALO ALTO, CALIF., US Inventor name: HOLMES, CHRIS, SARATOGA, CALIF., US |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: PETERS, H., DIPL.-BIOCHEM. DR.RER.NAT., PAT.-ANW., |